While your journey may look different than others, you can still forge your own path with advocacy, columnist Marisa Zeppieri ...

Brepocitinib, an investigational oral therapy, failed to show any benefits beyond a placebo in a Phase 2 clinical trial that tested it in adults with moderate to severely active systemic lupus ...

A single infusion of mesenchymal stem cells (MSCs) — those that make cells of the cartilage, bone, and fat — decreased the number of auto-reactive immune cells in difficult-to-treat systemic lupus ...

The first patient has been enrolled in RECAST DLE, a Phase 2 study evaluating daxdilimab, a potentially first-in-class therapy for moderate-to-severe discoid lupus erythematosus (DLE), a form of lupus ...

Telitacicept, a B-cell-targeting therapy developed by RemeGen, outperformed a placebo at reducing the severity of systemic lupus erythematosus (SLE) in a Phase 3 clinical trial in China, the company ...

Do you enjoy sweet potatoes? Did you know they’re a super food that contain many nutritional benefits? The World’s Healthiest Foods, list numerous benefits of incorporating sweet potatoes into your ...

If you want me to roll my eyes up in my head, tell me that faith will heal me. In your presence, I try to keep that visceral feeling to myself. But I have learned that my face often displays what I’m ...

Because lupus is such a complex disease, it affects people differently. Symptoms vary from person to person, which means the treatments have to be personalized. Lupus is an autoimmune inflammatory ...

Lupuzor (rigerimod, or IPP-201101) combined with standard therapy did not demonstrate a statistically significant response rate in systemic lupus erythematosus (SLE) patients over standard care alone, ...

Near the end of 2024, the support group Lupus in Color posted the following “lupus serenity prayer” on Instagram: “God, grant me the serenity to accept the changes and challenges of living with lupus, ...

Treatment with Benlysta (belimumab) induces meaningful and long-lasting reductions in systemic lupus erythematosus (SLE) disease activity, helping a significant proportion of patients achieve durable ...

Omalizumab — a treatment already approved for allergic asthma and chronic hives — is well-tolerated and reduces disease activity in patients with systemic lupus erythematosus (SLE), a Phase 1b ...